IN2015DN01115A - - Google Patents
Info
- Publication number
- IN2015DN01115A IN2015DN01115A IN1115DEN2015A IN2015DN01115A IN 2015DN01115 A IN2015DN01115 A IN 2015DN01115A IN 1115DEN2015 A IN1115DEN2015 A IN 1115DEN2015A IN 2015DN01115 A IN2015DN01115 A IN 2015DN01115A
- Authority
- IN
- India
- Prior art keywords
- polypeptide
- constructs
- heteromultimer
- monomeric
- transporter
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261671640P | 2012-07-13 | 2012-07-13 | |
US201261697245P | 2012-09-05 | 2012-09-05 | |
US201361758701P | 2013-01-30 | 2013-01-30 | |
US201361845945P | 2013-07-12 | 2013-07-12 | |
PCT/US2013/050408 WO2014012082A2 (en) | 2012-07-13 | 2013-07-12 | Multivalent heteromultimer scaffold design an constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN01115A true IN2015DN01115A (en) | 2015-06-26 |
Family
ID=49916710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1115DEN2015 IN2015DN01115A (en) | 2012-07-13 | 2013-07-12 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9388231B2 (en) |
JP (1) | JP6498601B2 (en) |
CN (1) | CN104768571B (en) |
AU (1) | AU2013289881B2 (en) |
CA (1) | CA2878640C (en) |
IN (1) | IN2015DN01115A (en) |
WO (1) | WO2014012082A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012058768A1 (en) | 2010-11-05 | 2012-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
CA2828811C (en) | 2011-03-03 | 2021-09-21 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
BR112014010580B1 (en) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct |
WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
WO2014012082A2 (en) * | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
EP3013942A4 (en) * | 2013-06-24 | 2016-11-23 | Anthrogenesis Corp | Methods of expanding t cells |
CN113150163A (en) | 2014-03-21 | 2021-07-23 | X博迪公司 | Bispecific antigen binding polypeptides |
US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
CN108137706A (en) | 2015-07-15 | 2018-06-08 | 酵活有限公司 | The bispecific antigen-binding constructs of drug conjugate |
CN109415423A (en) * | 2016-10-11 | 2019-03-01 | 威尔斯达眼科制剂公司 | The fusion protein of short retinal rod source property cone Active factor and hydrophilic peptide |
CN110520436A (en) | 2017-03-15 | 2019-11-29 | 潘迪恩治疗公司 | Target immunological tolerance |
JOP20190222A1 (en) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | Anti-pd-l1-anti-tim-3 bispecific antibodies |
US11531030B2 (en) | 2017-04-21 | 2022-12-20 | Mayo Foundation For Medical Education And Research | Polypeptide-antibody complexes and uses thereof |
JP2020521452A (en) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | Targeted tolerance |
AR112603A1 (en) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US20210023233A1 (en) * | 2018-02-06 | 2021-01-28 | Mayo Foundation For Medical Education And Research | Antibody-peptide complexes and uses thereof |
WO2019173911A1 (en) | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
CN113195544A (en) * | 2018-06-07 | 2021-07-30 | 库利南肿瘤股份有限公司 | Multispecific binding proteins and methods of use thereof |
KR102244760B1 (en) * | 2019-04-29 | 2021-04-27 | 주식회사 다나그린 | Porous scaffold including inducible protein from serum and manufacturing method of the same |
BR112021023345A2 (en) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Targeted immunotolerance in madcam |
AU2020282736A1 (en) * | 2019-05-29 | 2021-10-28 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
EP4218825A1 (en) * | 2020-09-25 | 2023-08-02 | Proabtech Inc. | Conjugate of functional polypeptide variant, and use thereof |
CN114736291B (en) * | 2021-01-07 | 2023-08-11 | 中国科学院微生物研究所 | Humanized monoclonal antibody specifically binding to envelope protein Gn of fever with thrombocytopenia syndrome virus and use thereof |
CN113563474B (en) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | EpCAM-CD16-NKG2D trispecific antibody and application thereof |
WO2023147042A2 (en) * | 2022-01-28 | 2023-08-03 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for treating cns disorders |
CN115057925B (en) * | 2022-06-22 | 2024-03-26 | 中国检验检疫科学研究院 | Anti-akabane virus monoclonal antibody and application thereof |
CN116990504B (en) * | 2023-09-27 | 2023-12-01 | 苏州旭光科星抗体生物科技有限公司 | Double antibody sandwich ELISA kit for detecting human soluble CD4 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JP2532858B2 (en) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | Transformed myeloma cell line |
GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
JPS6296086A (en) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | Composite plasmid |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
DK159088C (en) | 1988-04-06 | 1991-01-28 | Oce Helioprint As | SCANNING TO DETECT AN ORIGINAL |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
KR100195632B1 (en) | 1988-07-23 | 1999-06-15 | 스티븐 조지 가랜드 | New secretory leader sequences |
FR2649991B2 (en) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES |
DD275463A1 (en) | 1988-09-07 | 1990-01-24 | Forschungsstelle Fuer Medizini | PROCESS FOR THE PRODUCTION OF SERUMEI WHITE WITH INCREASED DIPOLOMENT FOR THERAPEUTIC USES |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US5780594A (en) | 1993-03-01 | 1998-07-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Biologically active protein fragments containing specific binding regions of serum albumin or related proteins |
US6001606A (en) | 1994-03-08 | 1999-12-14 | Human Genome Sciences, Inc. | Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1996034891A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4 |
US6291207B1 (en) | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4213224B2 (en) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | Method for producing multispecific antibody having heteromultimer and common component |
WO1999021571A1 (en) | 1997-10-27 | 1999-05-06 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
WO2001011046A1 (en) | 1999-08-05 | 2001-02-15 | Human Genome Sciences, Inc. | Dendritic enriched secreted lymphocyte activation molecule |
EP1088888A4 (en) | 1998-05-14 | 2005-03-16 | Merck Patent Gmbh | Fused protein |
WO2001007608A1 (en) | 1999-07-21 | 2001-02-01 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR20010101981A (en) | 1999-02-08 | 2001-11-15 | 벤슨 로버트 에이치. | Vascular endothelial growth factor-2 |
EP1218408A4 (en) | 1999-09-24 | 2003-02-26 | Human Genome Sciences Inc | 32 human secreted proteins |
DE19963859A1 (en) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins |
US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1832599A3 (en) | 2000-04-12 | 2007-11-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EA005584B1 (en) | 2000-12-07 | 2005-04-28 | Эли Лилли Энд Компани | Glp-1 fusion proteins |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
PT2279753E (en) | 2001-10-10 | 2016-01-15 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277910A1 (en) * | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004082640A2 (en) | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
CN101198698B (en) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | Process for production of polypeptide by regulation of assembly |
EP1945674A2 (en) | 2005-11-03 | 2008-07-23 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
US8441210B2 (en) | 2006-01-20 | 2013-05-14 | Point Somee Limited Liability Company | Adaptive current regulation for solid state lighting |
ES2549128T3 (en) | 2006-05-19 | 2015-10-23 | Technion Research And Development Foundation Ltd. | Fusion proteins, uses thereof and processes to produce them |
ES2469676T3 (en) | 2006-05-25 | 2014-06-18 | Bayer Intellectual Property Gmbh | Dimeric molecular complexes |
DK2256135T3 (en) | 2006-06-14 | 2019-06-11 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
US8580263B2 (en) | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
WO2009137911A1 (en) | 2008-05-15 | 2009-11-19 | National Research Counsil Of Canada | Process, vectors and engineered cell lines for enhanced large-scale transfection |
US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
WO2009012784A2 (en) | 2007-07-20 | 2009-01-29 | Nya Hamlet Pharma Ab | Methods for preparing cytotoxic complexes of emulsifier and fatty acid |
US8197196B2 (en) | 2007-08-31 | 2012-06-12 | General Electric Company | Bushing and clock spring assembly for moveable turbine vane |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
US9175078B2 (en) | 2008-01-25 | 2015-11-03 | Amgen Inc. | Ferroportin antibodies and methods of use |
AU2009221106A1 (en) * | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
US20120100558A1 (en) | 2008-09-08 | 2012-04-26 | Hanash Samir M | Lung cancer diagnosis |
JP5677972B2 (en) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | Human serum albumin linker and its conjugates |
JP5936112B2 (en) * | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | Albumin variants and complexes |
CA2757897A1 (en) * | 2009-04-08 | 2010-10-14 | Anna M. Wu | Human protein scaffold with controlled serum pharmacokinetics |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
CA2777242A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
EP2496598B1 (en) * | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
WO2011069090A1 (en) | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
AU2011235569B2 (en) | 2010-03-29 | 2016-06-30 | Zymeworks Bc Inc. | Antibodies with enhanced or suppressed effector function |
CN102946906B (en) * | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | Production of heteromultimeric proteins |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
EP2575880B1 (en) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
EA201291482A1 (en) | 2010-07-09 | 2013-10-30 | Байоджен Айдек Хемофилия Инк. | CHEMERIC COAGULATION FACTORS |
WO2012058768A1 (en) | 2010-11-05 | 2012-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
CA2828811C (en) * | 2011-03-03 | 2021-09-21 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
DK2748201T3 (en) | 2011-08-23 | 2018-02-12 | Roche Glycart Ag | BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES |
BR112014010580B1 (en) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct |
ES2843054T3 (en) | 2012-05-10 | 2021-07-15 | Zymeworks Inc | Heteromultimeric constructions of immunoglobulin heavy chains with mutations in the Fc domain |
KR20150008171A (en) | 2012-05-10 | 2015-01-21 | 자임워크스 인코포레이티드 | Single-arm monovalent antibody constructs and uses thereof |
WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
WO2014012082A2 (en) * | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
BR112015000798A2 (en) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
IN2015DN01299A (en) | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
EP2925785A4 (en) | 2012-11-28 | 2016-11-16 | Zymeworks Inc | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
CA2910945A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
EP3019622A4 (en) | 2013-07-12 | 2017-06-14 | Zymeworks Inc. | Bispecific cd3 and cd19 antigen binding contructs |
WO2017100363A1 (en) | 2015-12-08 | 2017-06-15 | Smartcar, Inc. | System and method for processing requests |
-
2013
- 2013-07-12 WO PCT/US2013/050408 patent/WO2014012082A2/en active Application Filing
- 2013-07-12 IN IN1115DEN2015 patent/IN2015DN01115A/en unknown
- 2013-07-12 CN CN201380036536.2A patent/CN104768571B/en active Active
- 2013-07-12 AU AU2013289881A patent/AU2013289881B2/en active Active
- 2013-07-12 CA CA2878640A patent/CA2878640C/en active Active
- 2013-07-12 JP JP2015521875A patent/JP6498601B2/en active Active
- 2013-07-13 US US13/941,450 patent/US9388231B2/en active Active
-
2016
- 2016-01-19 US US15/001,078 patent/US10358479B2/en active Active
-
2019
- 2019-05-21 US US16/417,969 patent/US11248037B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014012082A3 (en) | 2014-04-03 |
CA2878640C (en) | 2023-10-24 |
CN104768571A (en) | 2015-07-08 |
CN104768571B (en) | 2018-11-09 |
CA2878640A1 (en) | 2014-01-16 |
AU2013289881A1 (en) | 2015-02-26 |
US11248037B2 (en) | 2022-02-15 |
AU2013289881B2 (en) | 2018-01-18 |
US20140066378A1 (en) | 2014-03-06 |
US9388231B2 (en) | 2016-07-12 |
JP6498601B2 (en) | 2019-04-10 |
US10358479B2 (en) | 2019-07-23 |
WO2014012082A2 (en) | 2014-01-16 |
US20190375823A1 (en) | 2019-12-12 |
US20160207979A1 (en) | 2016-07-21 |
JP2015524799A (en) | 2015-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN01115A (en) | ||
EA201290722A1 (en) | RECOMBINANT PROTEIN EXENDIN-4 AND ITS ANALOGUE, METHOD OF THEIR PREPARATION AND USE | |
EA201190326A8 (en) | GROWTH HORMONE POLYPEPTIDES AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
WO2013184938A3 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
MY191428A (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
IN2014DN02043A (en) | ||
WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
IN2014DN09815A (en) | ||
EA201491494A1 (en) | NACELIVANIE NA GLIKANY HONDROITINSULFATY | |
EA201691304A1 (en) | ANTAGONISTS OF NEONATAL Fc-RECEPTORS (FcRn) AND METHODS OF THEIR APPLICATION | |
MX350962B (en) | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects. | |
IN2014CN00414A (en) | ||
BR112016002753A2 (en) | antibodies to plasminogen activator inhibitor-1 (parent-1) and uses thereof | |
AR092076A1 (en) | HOMODIMERIC PROTEINS | |
UA97516C2 (en) | Fully human anti-vap-1 monoclonal antibody | |
BR112014024282A2 (en) | bradykinin b1 receptor binding antibodies | |
PE20121636A1 (en) | IL-2 DERIVED IMMUNOMODULATOR POLYPEPTIDES AND THEIR THERAPEUTIC USE IN CANCER AND CHRONIC INFECTIONS | |
TR201905619T4 (en) | Peptide carrier fusion proteins as allergy vaccines. | |
MX366178B (en) | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof. | |
MX2016011394A (en) | Stabilized fibronectin based scaffold molecules. | |
SG10201903142RA (en) | Serpin fusion polypeptides and methods of use thereof | |
BR112015003724A2 (en) | isolated polypeptide, composition, use of a composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, and methods of producing a polypeptide and producing a protein. | |
BR112015008673A2 (en) | compound, pharmaceutical composition and method | |
MY187130A (en) | Variants of gal2 transporter and their uses | |
WO2012122378A3 (en) | Antibody-like proteins for therapeutic and diagnostic use |